Saturna Capital Corp Increases Position in Kenvue Inc. (NYSE:KVUE)

Saturna Capital Corp increased its holdings in Kenvue Inc. (NYSE:KVUE) by 29.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,334,860 shares of the company’s stock after acquiring an additional 307,039 shares during the quarter. Saturna Capital Corp owned approximately 0.07% of Kenvue worth $30,875,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Leo Wealth LLC raised its stake in shares of Kenvue by 0.3% in the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock valued at $3,507,000 after purchasing an additional 481 shares in the last quarter. Massmutual Trust Co. FSB ADV raised its stake in Kenvue by 6.2% during the third quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock valued at $194,000 after buying an additional 492 shares in the last quarter. Wolff Wiese Magana LLC lifted its holdings in Kenvue by 0.7% during the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after buying an additional 501 shares during the last quarter. Marathon Capital Management lifted its holdings in Kenvue by 0.3% during the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock worth $2,722,000 after buying an additional 514 shares during the last quarter. Finally, Poehling Capital Management INC. grew its position in shares of Kenvue by 0.5% in the 2nd quarter. Poehling Capital Management INC. now owns 104,934 shares of the company’s stock worth $1,908,000 after acquiring an additional 547 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Up 0.1 %

Shares of KVUE stock opened at $23.48 on Wednesday. The firm has a market capitalization of $45.02 billion, a PE ratio of 43.00, a price-to-earnings-growth ratio of 3.08 and a beta of 1.36. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $23.95. The stock has a fifty day moving average of $22.68 and a two-hundred day moving average of $20.58.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The firm had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. Kenvue’s revenue was down .4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.31 EPS. As a group, research analysts expect that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.49%. The ex-dividend date of this dividend is Wednesday, November 13th. Kenvue’s payout ratio is currently 149.09%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on KVUE. JPMorgan Chase & Co. raised their price objective on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Royal Bank of Canada lowered shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target for the company. in a report on Tuesday, September 24th. UBS Group boosted their price objective on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, Bank of America upped their target price on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.